CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lobe Sciences Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lobe Sciences Ltd
1400-1199 West Hastings Street
Phone: (604) 834-9499p:604 834-9499 VANCOUVER, BC  V6E 3T5  Canada Ticker: LOBELOBE
Business Summary
Lobe Sciences, Ltd. is a biopharmaceutical company focused on using lipid technology to develop treatments for orphan and rare diseases. The Company, through its wholly owned subsidiaries, Alera Pharma, Inc. and Altemia, Inc., is advancing the development of a patented drug candidate aimed at treating neurological disorders, with an initial focus on chronic cluster headache (Alera). The Company commercializes Altemia MF, a medical food designed to manage deficiencies commonly found in sickle cell disease. Additionally, through Cynaptec Pharmaceuticals, Inc. (Cynaptec), the Company retains an interest in developing Conjugated Psilocin in neurology and psychiatric indications. Conjugated Psilocin is a patented, oral, stable analog of psilocin, the active metabolite of the prodrug psilocybin, designed to enhance bioavailability and therapeutic efficacy, which has been identified as having therapeutic potential in a variety of neurological conditions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
2/28/20258/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Frederick D.Sancilio 73 8/12/2024 8/12/2024
Chief Financial Officer, Executive Vice President YongYao 6/1/2025 6/1/2025
Director RickGoulburn 8/12/2024 8/12/2024
3 additional Officers and Directors records available in full report.

Business Names
Business Name
BET
BET.H
GSTR
LOBE

General Information
Outstanding Shares: 192,652,124 (As of 2/28/2025)
Stock Exchange: CNQ
Fax Number: (604) 628-1249


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, June 28, 2025